KATHY HEMMING: Open Payments
NPI 1700817442 · AMMON, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$470 in 14 payments from 6 companies in 2025. Trend: 2023 $294 · 2024 $200 · 2025 $470
Food & beverage: $470
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $187 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 4 | $72 |
| ABBVIE INC. | 3 | $49 |
| Alkermes, Inc. | 1 | $22 |
| Neurocrine BioSciences, Inc. | 1 | $15 |
Products named: CAPLYTA, UZEDY, FANAPT, VRAYLAR, VIVITROL, INGREZZA.
Industry payments across ID — which companies pay providers there.
